AVTX
Price
$9.05
Change
+$0.11 (+1.23%)
Updated
Aug 15, 01:32 PM (EDT)
Capitalization
117.71M
MESO
Price
$16.21
Change
+$0.35 (+2.21%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
2.03B
12 days until earnings call
Interact to see
Advertisement

AVTX vs MESO

Header iconAVTX vs MESO Comparison
Open Charts AVTX vs MESOBanner chart's image
Avalo Therapeutics
Price$9.05
Change+$0.11 (+1.23%)
Volume$3.57K
Capitalization117.71M
Mesoblast
Price$16.21
Change+$0.35 (+2.21%)
Volume$3.43K
Capitalization2.03B
AVTX vs MESO Comparison Chart in %
Loading...
AVTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVTX vs. MESO commentary
Aug 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVTX is a Hold and MESO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2025
Stock price -- (AVTX: $8.95 vs. MESO: $15.86)
Brand notoriety: AVTX and MESO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVTX: 468% vs. MESO: 117%
Market capitalization -- AVTX: $117.71M vs. MESO: $2.03B
AVTX [@Biotechnology] is valued at $117.71M. MESO’s [@Biotechnology] market capitalization is $2.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVTX’s FA Score shows that 2 FA rating(s) are green whileMESO’s FA Score has 0 green FA rating(s).

  • AVTX’s FA Score: 2 green, 3 red.
  • MESO’s FA Score: 0 green, 5 red.
According to our system of comparison, AVTX is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVTX’s TA Score shows that 4 TA indicator(s) are bullish while MESO’s TA Score has 6 bullish TA indicator(s).

  • AVTX’s TA Score: 4 bullish, 4 bearish.
  • MESO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MESO is a better buy in the short-term than AVTX.

Price Growth

AVTX (@Biotechnology) experienced а +7.19% price change this week, while MESO (@Biotechnology) price change was +3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.55%. For the same industry, the average monthly price growth was +20.96%, and the average quarterly price growth was +20.84%.

Reported Earning Dates

MESO is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Biotechnology (+5.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MESO($2.03B) has a higher market cap than AVTX($118M). AVTX YTD gains are higher at: 20.458 vs. MESO (-19.899). AVTX has higher annual earnings (EBITDA): -50.14M vs. MESO (-77.78M). AVTX has more cash in the bank: 125M vs. MESO (37.7M). AVTX has less debt than MESO: AVTX (801K) vs MESO (126M). MESO has higher revenues than AVTX: MESO (5.67M) vs AVTX (441K).
AVTXMESOAVTX / MESO
Capitalization118M2.03B6%
EBITDA-50.14M-77.78M64%
Gain YTD20.458-19.899-103%
P/E Ratio1.37N/A-
Revenue441K5.67M8%
Total Cash125M37.7M332%
Total Debt801K126M1%
FUNDAMENTALS RATINGS
AVTX vs MESO: Fundamental Ratings
AVTX
MESO
OUTLOOK RATING
1..100
1786
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
595
PRICE GROWTH RATING
1..100
3538
P/E GROWTH RATING
1..100
297
SEASONALITY SCORE
1..100
4350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVTX's Valuation (85) in the Pharmaceuticals Other industry is in the same range as MESO (88) in the Biotechnology industry. This means that AVTX’s stock grew similarly to MESO’s over the last 12 months.

AVTX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MESO (100) in the Biotechnology industry. This means that AVTX’s stock grew similarly to MESO’s over the last 12 months.

AVTX's SMR Rating (5) in the Pharmaceuticals Other industry is significantly better than the same rating for MESO (95) in the Biotechnology industry. This means that AVTX’s stock grew significantly faster than MESO’s over the last 12 months.

AVTX's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as MESO (38) in the Biotechnology industry. This means that AVTX’s stock grew similarly to MESO’s over the last 12 months.

AVTX's P/E Growth Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for MESO (97) in the Biotechnology industry. This means that AVTX’s stock grew significantly faster than MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVTXMESO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
AVTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FFNAX13.89N/A
N/A
Fidelity Advisor Asset Manager 40% A
NBREX26.82N/A
N/A
Neuberger Berman M/C Intrinsic Val Tr
HLGEX54.39N/A
N/A
JPMorgan Mid Cap Growth I
IWEDX13.87N/A
N/A
Voya Large Cap Value W
VGHRX52.06N/A
N/A
Voya Global High Dividend Low Vol R6

AVTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVTX has been loosely correlated with FGEN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if AVTX jumps, then FGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVTX
1D Price
Change %
AVTX100%
-1.38%
FGEN - AVTX
57%
Loosely correlated
-4.05%
MEOBF - AVTX
46%
Loosely correlated
+1.99%
MRSN - AVTX
37%
Loosely correlated
+8.96%
PGEN - AVTX
34%
Loosely correlated
-3.14%
BDRX - AVTX
32%
Poorly correlated
+1.88%
More